# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Argus Research analyst Jasper Hellweg upgrades Illumina (NASDAQ:ILMN) from Hold to Buy and announces $150 price target.
TruSight Oncology Comprehensive is the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-ca...
Daiwa Capital analyst Narumi Nakagiri upgrades Illumina (NASDAQ:ILMN) from Neutral to Buy and raises the price target from $...
Scotiabank analyst Sung Ji Nam maintains Illumina (NASDAQ:ILMN) with a Sector Outperform and lowers the price target from $1...